GRFS
Grifols, S.A.
Set alert
- YTD
- -13.37%
- 1 year
- -11.57%
- Open
- 8.10
- Prev close
- 8.04
- Mkt cap
- 5.51B
- Vol
- 803.38K
- Avg vol
- 530.76K
- EPS
- 0.77
- P/E
- 10.52
- Div yield
- 1.32%
More statistics
- Low
- 8.05
- High
- 8.25
- Forward P/E
- 6.08
- Beta
- 1.20
- Short ratio
- 11.06
- Inst. own
- 57.27%
- Dividend
- 0.11
- Ex-div date
- Jul 1, 2026
- Earnings
- Nov 2, 2026
- 50-d avg
- 7.59
- 200-d avg
- 8.00
- 1y target
- 10.37
Key statistics
- Market cap
- 5.51B
- Enterprise value
- 22.20B
- Trailing P/E
- 10.52
- Forward P/E
- 6.08
- PEG ratio
- 0.19
- Price / sales
- 0.74
- Price / book
- 1.77
- EPS (TTM)
- 0.77
- Beta
- 1.20
- Dividend yield
- 1.32%
- Payout ratio
- 37.97%
- Profit margin
- 6.09%
- Revenue (TTM)
- 7.42B
- Revenue growth
- -0.90%
- Free cash flow
- 572.92M
- Total cash
- 537.00M
- Total debt
- 9.36B
- Return on equity
- 6.93%
- Shares outstanding
- 258.22M
- Short % of float
- 0.00%
- 50-day average
- 7.59
- 200-day average
- 8.00
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 10.37
- Target (high)
- 11.73
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.30396.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.3202 | — | — | — |
| Jul 28, 2026 | Jun 30, 2026 | 0.27 | 0.2512 | -0.02 | -6.96% |
| May 7, 2026 | Mar 31, 2026 | 0.1613 | 0.1731 | +0.01 | +7.32% |
| Feb 26, 2026 | Dec 31, 2025 | 0.29 | 0.2891 | 0.00 | -0.31% |
| Nov 4, 2025 | Sep 30, 2025 | 0.2417 | 0.2108 | -0.03 | -12.78% |
| Jul 29, 2025 | Jun 30, 2025 | 0.23 | 0.19 | -0.04 | -17.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | JP Morgan | main | Neutral | Neutral |
| Dec 8, 2025 | JP Morgan | main | Neutral | Neutral |
| Jun 17, 2025 | JP Morgan | main | Neutral | Neutral |
| Mar 12, 2024 | Deutsche Bank | down | Hold | Sell |
| Dec 5, 2023 | JP Morgan | main | Neutral | Neutral |
| Nov 5, 2021 | Deutsche Bank | down | Buy | Hold |
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Spain
- Website
- grifols.com
News
- Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
- Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
- Grifols says Canada plasma license suspension has no impact
- Grifols: Better Plasma Economics Can Unlock A Discounted Equity
- Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
- GRFS or SDZNY: Which Is the Better Value Stock Right Now?
- Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
- Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
- Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on GRFS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Brandes Investment Partners L.P. | 14.47% | 37,816,285 | 306.31M | Jun 29, 2026 |
| Capital World Investors | 8.76% | 22,911,656 | 185.58M | Jun 29, 2026 |
| Permian Investment Partners, Lp | 7.55% | 19,740,679 | 159.90M | Jun 29, 2026 |
| Black Creek Investment Management Inc. | 2.94% | 7,682,055 | 62.22M | Jun 29, 2026 |
| Bank of America Corporation | 2.51% | 6,550,337 | 53.06M | Jun 29, 2026 |
| Millennium Management Llc | 1.67% | 4,369,934 | 35.40M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEW PERSPECTIVE FUND | 5.37% | 14,039,027 | 113.72M | Sep 29, 2026 |
| Intl Growth & Income Fd.-Intl Growth and Income Fd. | 1.98% | 5,180,416 | 41.96M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.84% | 4,803,459 | 38.91M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.69% | 1,812,126 | 14.68M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES SMALL CAP VALUE FUND | 0.63% | 1,647,438 | 13.34M | Jun 29, 2026 |
| 2023 ETF Series Trust-Brandes International ETF | 0.34% | 893,153 | 7.23M | Jun 29, 2026 |